First us coronavirus vaccine test to start monday

You're referring to the first human trial of a potential COVID-19 vaccine!

Yes, you're correct. On March 16, 2020, the first human trial of a potential COVID-19 vaccine, developed by Moderna Therapeutics, was set to begin in the United States. The trial, known as the Phase 1 trial, aimed to test the safety and efficacy of the vaccine in healthy adults.

The vaccine, called mRNA-1273, uses a piece of genetic material called messenger RNA (mRNA) to instruct cells in the body to produce a protein that triggers an immune response. This approach is known as a messenger RNA (mRNA) vaccine.

The trial was designed to enroll 45 healthy adults aged 18-55, who would receive two doses of the vaccine, 28 days apart. The participants would be monitored for adverse reactions and immune responses, including the production of antibodies and T-cells.

The trial was conducted at Kaiser Permanente Washington Health Research Institute in Seattle, Washington, and was led by Dr. Lisa Jackson, an infectious disease specialist.

The results of the trial were published in The New England Journal of Medicine on March 16, 2020, and showed that the vaccine was safe and induced a strong immune response in participants. The vaccine was found to be well-tolerated, with mild side effects such as pain, redness, and swelling at the injection site.

The success of this trial paved the way for further testing and development of the vaccine, which has since been approved for emergency use in many countries around the world.